KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (ONC) Equity Ratio (2016 - 2025)

BeOne Medicines (ONC) has disclosed Equity Ratio for 11 consecutive years, with 0.6 as the latest value for Q2 2025.

  • On a quarterly basis, Equity Ratio changed N/A to 0.6 in Q2 2025 year-over-year; TTM through Jun 2025 was 0.6, a N/A change, with the full-year FY2024 number at 0.56, down 23.37% from a year prior.
  • Equity Ratio was 0.6 for Q2 2025 at BeOne Medicines, up from 0.56 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.8 in Q4 2022 to a low of 0.56 in Q4 2024.
  • A 5-year average of 0.67 and a median of 0.66 in 2023 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: rose 11.31% in 2022, then dropped 23.37% in 2024.
  • BeOne Medicines' Equity Ratio stood at 0.72 in 2021, then grew by 11.31% to 0.8 in 2022, then dropped by 8.16% to 0.73 in 2023, then dropped by 23.37% to 0.56 in 2024, then rose by 6.37% to 0.6 in 2025.
  • Per Business Quant, the three most recent readings for ONC's Equity Ratio are 0.6 (Q2 2025), 0.56 (Q4 2024), and 0.59 (Q1 2024).